Afeyan Noubar's Form 4 filing
Omega Therapeutics, Inc. (OMGA) · filed Feb 27, 2023
- Accession no.
- 0000899243-23-006241
- Filed
- Feb 27, 2023, 5:20 PM ET
- Trade date
- Feb 27, 2023
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $19.2M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Afeyan NoubarCIK 0001222012 | Director, 10% Owner |
| Flagship Pioneering, LLCCIK 0001400240 | 10% Owner |
| Flagship Pioneering Special Opportunities Fund II, L.P.CIK 0001761283 | 10% Owner |
| Flagship Pioneering Special Opportunities Fund II General Partner LLCCIK 0001826217 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2023 | Common Stock | PPurchaseAcquired | +1,993,986 | $5.78 | +$11,525,239.08 | 7,508,693 | Indirect | |
| Feb 27, 2023 | Common Stock | PPurchaseAcquired | +1,329,324 | $5.78 | +$7,683,492.72 | 1,329,324 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.